TD Cowen initiated coverage of Akero Therapeutics (AKRO) with a Buy rating and $76 price target The firm believes the company’s efruxifermin, an FGF21 analog, has a “differentiated” clinical profile and see commercial success in metabolic dysfunction-associated steatohepatitis. Efruxifermin, is in Phase 3 trials with high probabilities of success, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics Advances Efruxifermin Study for NASH Treatment
- Akero Therapeutics Advances Phase 3 Study on Efruxifermin for NASH/MASH Cirrhosis
- Akero Therapeutics Advances Phase 3 Study on Efruxifermin for NASH/MASH Treatment
- Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
- Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets